Human cytochromes P450 in health and disease

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 368, Issue 1612, 2013, Pages

  Nebert, Daniel W ^a   Wikvall, Kjell ^b   Miller, Walter L ^c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bile acids; Drug metabolizing enzymes; Eicosanoids; Retinoids; Steroidogenesis; Vitamin d biosynthesis

Indexed keywords

CYTOCHROME; DISEASE INCIDENCE; EMBRYO; ENZYME ACTIVITY; FATTY ACID; GENOME; METABOLISM; MOLECULAR ANALYSIS; MUTATION; PHEROMONE; RODENT; VITAMIN;

MAMMALIA; RODENTIA;

CHOLESTEROL; CYTOCHROME P450; ICOSANOID; PRASTERONE; PREGNENOLONE; RETINOIC ACID; VITAMIN D;

ANIMAL; BIOSYNTHESIS; CLASSIFICATION; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; HUMAN; HYDROXYLATION; METABOLIC DISORDER; METABOLISM; MOLECULAR EVOLUTION; MULTIGENE FAMILY; OXIDATION REDUCTION REACTION; PATHOLOGY; REVIEW;

ANIMALS; CHOLESTEROL; CYTOCHROME P-450 ENZYME SYSTEM; DEHYDROEPIANDROSTERONE; EICOSANOIDS; ENZYME ACTIVATION; EVOLUTION, MOLECULAR; HUMANS; HYDROXYLATION; METABOLIC DISEASES; MULTIGENE FAMILY; OXIDATION-REDUCTION; PREGNENOLONE; TRETINOIN; VITAMIN D;

MLCS; MLOWN;

EID: 84880144950     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2012.0431     Document Type: Review

References (169)

1. Klingenberg M. 1958 Pigments of rat liver microsomes. Arch. Biochem. Biophys. 75, 376-386.(doi:10.1016/0003-9861(58)90436-3)
2. Garfinkel D. 1958 Studies on pig liver microsomes. I. Enzymic and pigment composition of different microsomal fractions. Arch. Biochem. Biophys. 77, 493-509.(doi:10.1016/0003- 9861(58)90095-X)
3. Omura T, Sato R. 1962 A new cytochrome in liver microsomes. J. Biol. Chem. 237, 1375-1376.
4. Conney AH. 1967 Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 19, 317-366.
5. Gillette JR, Davis DC, Sasame HA. 1972 Cytochrome P-450 and its role in drug metabolism. Annu. Rev. Pharmacol. 12, 57-84.(doi:10.1146/annurev.pa.12. 040172.000421)
6. Wada O, Yano Y. 1974 Adaptive responses of liver to foreign compounds, with special reference to microsomal drug-metabolizing enzymes. Rev. Environ. Health 1, 261-282.
7. Parke DV. 1975 Induction of the drug-metabolizing enzymes. Basic Life. Sci. 6, 207-271.
8. Cooper DY, Estabrook RW, Rosenthal O. 1963 Stoichiometry of C21 hydroxylation of steroids by adrenocortical microsomes. J. Biol. Chem. 238, 1320-1323.
9. Orrenius S. 1968 Some aspects on the hydroxylation of drugs, steroid hormones, and fatty acids (v-oxidation) in rat liver microsomes. Hoppe Seylers Z. Physiol. Chem. 349, 1619-1621.
10. Shimizu T, Nozawa T, Hatano M, Imai Y, Sato R. 1975 Magnetic circular dichroism studies of hepatic microsomal cytochrome P-450. Biochemistry 14, 4172-4178.(doi:10.1021/bi00690a004)
11. Sato M, Kon H, Kumaki K, Nebert DW. 1977 Comparative EPR study on high-spin ferric porphine complexes and cytochrome P-450 having rhombic character. Biochim. Biophys. Acta 498, 403-421.(doi:10.1016/0304-4165(77)90279-3)
12. Hatano M, Nozawa T. 1978 Magnetic circular dichroism approach to hemoprotein analyses. Adv. Biophys. 11, 95-149.
13. Ruf HH, Wende P, Ullrich V. 1979 Models for ferric cytochrome P450. Characterization of hemin mercaptide complexes by electronic and ESR spectra. J. Inorg. Biochem. 11, 189-204.(doi:10.1016/S0162-0134(00)80017-3)
14. Nebert DW, Gonzalez FJ. 1987 P450 genes: structure, evolution, and regulation. Annu. Rev. Biochem. 56, 945-993.(doi:10.1146/annurev.bi.56. 070187.004501)
15. Nebert DW et al. 1987 The P450 gene superfamily: recommended nomenclature. DNA 6, 1-11.(doi:10.1089/dna.1987.6.1)
16. Nelson DR et al. 1996 P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 6, 1-42.(doi:10.1097/00008571-199602000-00002)
17. Nebert DW, Dalton TP. 2006 The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer 6, 947-960.(doi:10.1038/nrc2015)
18. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. 2004 Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes, and alternative-splice variants. Pharmacogenetics 14, 1-18.(doi:10.1097/ 00008571-200401000-00001)
19. Nebert DW. 1991 Proposed role of drugmetabolizing enzymes: regulation of steady-state levels of ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions. Mol. Endocrinol. 5, 1203-1214.(doi:10.1210/mend- 5-9-1203)
20. Xia C, Panda SP, Marohnic CC, Martasek P, Masters BS, Kim JJ. 2011 Structural basis for human NADPHcytochrome P450 oxidoreductase deficiency. Proc. Natl Acad. Sci. USA 108, 13 486-13 491.(doi:10. 1073/pnas.1106632108)
21. Xia C et al. 2011 Conformational changes of NADPHcytochrome P450 oxidoreductase are essential for catalysis and cofactor binding. J. Biol. Chem. 286, 16 246-16 260.(doi:10.1074/jbc.M111. 230532)
22. Fluck CE et al. 2004 Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat. Genet. 36, 228-230.(doi:10.1038/ng1300)
23. Huang N et al. 2005 Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 76, 729-749.(doi:10.1086/429417)
24. Tomalik-Scharte D, Maiter D, Kirchheiner J, Ivison HE, Fuhr U, Arlt W. 2010 Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur. J. Endocrinol. 163, 919-924.(doi:10.1530/EJE- 10-0764)
25. Kok RC, Timmerman MA, Wolffenbuttel KP, Drop SL, de Jong FH. 2010 Isolated 17,20-lyase deficiency due to the cytochrome b5 mutation W27X. J. Clin. Endocrinol. Metab. 95, 994-999.(doi:10.1210/jc. 2008-1745)
26. Dong H et al. 2009 Knock-in mouse lines expressing either mitochondrial or microsomal CYP1A1: differing responses to dietary benzo[a]pyrene as proof of principle. Mol. Pharmacol. 75, 555-567.(doi:10.1124/mol.108.051888)
27. Avadhani NG, Sangar MC, Bansal S, Bajpai P. 2011 Bimodal targeting of cytochromes P450 to endoplasmic reticulum and mitochondria: the concept of chimeric signals. FEBS. J. 278, 4218-4229.(doi:10.1111/j.1742-4658.2011.08356.x)
28. Conney AH, Miller EC, Miller JA. 1956 Metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in rat by 3- methylcholanthrene. Cancer Res. 16, 450-459.
29. Remmer H, Merker HJ. 1963 Enzyme induction and increase of endoplasmic reticulum in liver cells during phenobarbital (Luminal) therapy. Klin. Wochenschr. 41, 276-282.(doi:10.1007/ BF01483392)
30. Lu AY, Somogyi A, West S, Kuntzman R, Conney AH. 1972 Pregnenolone-16a-carbonitrile: a new type of inducer of drug-metabolizing enzymes. Arch. Biochem. Biophys. 152, 457-462.(doi:10.1016/ 0003-9861(72)90239-1)
31. Marshall WJ. 1971 Role of steroid hormones in hepatic microsomal enzyme induction. Biochem. Pharmacol. 20, 1723-1725.(doi:10.1016/0006- 2952(71)90308-X)
32. Luoma P, Vorne M. 1973 Combined effect of ethanol and phenobarbital on the activities of hepatic drug-metabolizing enzymes in rats. Acta Pharmacol. Toxicol. (Copenh). 33, 442-448.(doi:10. 1111/j.1600-0773.1973.tb01545.x)
33. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P. 1989 Increase in urinary excretion of 6b-hydroxycortisol as a marker of human hepatic cytochrome P450 IIIA induction. Br. J. Clin. Pharmacol. 28, 373-387.(doi:10.1111/j.1365-2125.1989.tb03516.x)
34. Aoyama T, Hardwick JP, Imaoka S, Funae Y, Gelboin HV, Gonzalez FJ. 1990 Clofibrate-inducible rat hepatic P450s IVA1 and IVA3 catalyze the v- and (v-1)-hydroxylation of fatty acids and the v-hydroxylation of prostaglandins E1 and F2a. J. Lipid. Res. 31, 1477-1482.
35. Gonzalez FJ, Nebert DW. 1990 Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive, and human genetic differences in drug oxidation. Trends. Genet. 6, 182-186.(doi:10.1016/ 0168-9525(90)90174-5)
36. Miller MA, Hales CA. 1979 Role of cytochrome P-450 in alveolar hypoxic pulmonary vasoconstriction in dogs. J. Clin. Invest. 64, 666-673.(doi:10.1172/ JCI109507)
37. Mohandas J, Duggin GG, Horvath JS, Tiller DJ. 1981 Regional differences in peroxidatic activation of paracetamol (acetaminophen) mediated by cytochrome P450 and prostaglandin endoperoxide synthetase in rabbit kidney. Res. Commun. Chem. Pathol. Pharmacol. 34, 69-80.
38. Schwartzman M, Carroll MA, Ibraham NG, Ferreri NR, Songu-Mize E, McGiff JC. 1985 Renal arachidonic acid metabolism. The third pathway. Hypertension 7, I136-I144.(doi:10.1161/01.HYP.7. 3_Pt_2.I136)
39. Makita K, Falck JR, Capdevila JH. 1996 Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system. FASEB. J. 10, 1456-1463.
40. Nebert DW, Karp CL. 2008 Endogenous functions of the aryl hydrocarbon receptor (AHR): intersection of cytochrome P450 1 (CYP1)-metabolized eicosanoids and AHR biology. J. Biol. Chem. 283, 36 061-36065.(doi:10.1074/jbc.R800053200)
41. Jennings BL, Anderson LJ, Estes AM, Yaghini FA, Fang XR, Porter J, Gonzalez FJ, Campbell WB, Malik KU. 2012 Cytochrome P450 1B1 contributes to renal dysfunction and damage caused by angiotensin II in mice. Hypertension 59, 348-354.(doi:10.1161/ HYPERTENSIONAHA.111.183301)
42. Dragin N, Shi Z, Madan R, Karp CL, Sartor MA, Chen C, Gonzalez FJ, Nebert DW. 2008 Phenotype of the Cyp1a1/1a2/1b1(2/2) triple-knockout mouse. Mol. Pharmacol. 73, 1844-1856.(doi:10.1124/mol. 108.045658)
43. Nebert DW, Gálvez-Peralta M, Shi Z, Dragin N. 2010 Inbreeding and epigenetics: beneficial as well as deleterious effects. Nat. Rev. Genet. 11, 662.(doi:10.1038/nrn2926)
44. van Herwaarden AE et al. 2007 Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Invest. 117, 3583-3592.(doi:10.1172/JCI33435)
45. Hasegawa M, Kapelyukh Y, Tahara H, Seibler J, Rode A, Krueger S, Lee DN, Wolf CR, Scheer N. 2011 Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4-mediated drugdrug interaction in a novel multiple humanized mouse line. Mol. Pharmacol. 80, 518-528.(doi:10.1124/mol.111.071845)
46. Scheer N et al. 2011 Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol. Pharmacol. 80, 63-72.
47. Scheer N, Kapelyukh Y, Chatham L, Rode A, Buechel S, Wolf CR. 2012 Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. Mol. Pharmacol. 82, 1022-1029.(doi:10.1124/mol.112.080036)
48. Li A et al. 2004 Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. Am. J. Hum. Genet. 74, 817-826.(doi:10.1086/383228)
49. Lefevre C, Bouadjar B, Ferrand V, Lefevre C. 2006 Mutations in a new cytochrome P450 gene in lamellar ichthyosis type-3. Hum. Mol. Genet. 15, 767-776.(doi:10.1093/hmg/ddi491)
50. Nakagawa K, Holla VR, Wei Y, Nakagawa K. 2006 Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J. Clin. Invest. 116, 1696-1702.(doi:10.1172/JCI27546)
51. Lundqvist E, Johansson I, Ingelman-Sundberg M. 1999 Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226, 327-338.(doi:10.1016/S0378- 1119(98)00567-8)
52. Eichelbaum M, Evert B. 1996 Influence of pharmacogenetics on drug disposition and response. Clin. Exp. Pharmacol. Physiol. 23, 983-985.(doi:10.1111/j.1440-1681.1996.tb01154.x)
53. Voronov P, Przybylo HJ, Jagannathan N. 2007 Apnea in a child after oral codeine: a genetic variant-an ultra-rapid metabolizer. Paediatr. Anaesth. 17, 684-687.(doi:10.1111/j.1460-9592. 2006.02182.x)
54. Nebert DW, Vesell ES. In press. Pharmacogenetics and pharmacogenomics. In Emery & Rimoin's principles and practice of medical genetics (eds DL Rimoin, JM Connor, RE Pyeritz, BR Korf), London, UK: Churchill Livingstone.
55. Ullrich V, Castle L, Weber P. 1981 Spectral evidence for the cytochrome P450 nature of prostacyclin synthetase. Biochem. Pharmacol. 30, 2033-2036.(doi:10.1016/0006-2952(81)90218-5)
56. Wang LH, Kulmacz RJ. 2002 Thromboxane synthase: structure and function of protein and gene. Prostaglandins Other Lipid. Mediat. 68-69, 409-422.(doi:10.1016/S0090-6980(02)00045-X)
57. Ullrich V, Hecker M. 1990 A concept for the mechanism of prostacyclin and thromboxane A2 biosynthesis. Adv. Prostaglandin Thromboxane Leukot. Res. 20, 95-101.
58. Isidor B et al. 2007 A gene responsible for Ghosal hemato-diaphyseal dysplasia maps to chromosome 7q33-34. Hum. Genet. 121, 269-273.(doi:10. 1007/s00439-006-0311-1)
59. Nakayama T et al. 2002 Splicing mutation of the prostacyclin synthase gene in a family associated with hypertension. Biochem. Biophys. Res. Commun. 297, 1135-1139.(doi:10.1016/S0006- 291X(02)02341-0)
60. Hiroi T, Imaoka S, Funae Y. 1998 Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 249, 838-843.(doi:10. 1006/bbrc.1998.9232)
61. Bromek E, Haduch A, Golembiowska K, Daniel WA. 2011 Cytochrome P450 mediates dopamine formation in the brain in vivo. J. Neurochem. 118, 806-815.(doi:10.1111/j.1471-4159.2011.07339.x)
62. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ. 2003 Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13, 173-181.(doi:10. 1097/00008571-200303000-00007)
63. Yu AM, Idle JR, Herraiz T, Kupfer A, Gonzalez FJ. 2003 Screening for endogenous substrates reveals that CYP2D6 is a 5- methoxyindolethylamine O-demethylase. Pharmacogenetics 13, 307-319.(doi:10.1097/ 00008571-200306000-00002)
64. Ingelman-Sundberg M. 2005 Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6 gene): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13.(doi:10.1038/sj.tpj.6500285)
65. Roberts RL, Luty SE, Mulder RT, Joyce PR, Kennedy MA. 2004 Association between cytochrome CYP2D6 genotype and harm avoidance. Am. J. Med. Genet. B Neuropsychiatr. Genet. 127B, 90-93.(doi:10.1002/ ajmg.b.20163)
66. Chiang JY. 2009 Bile acids: regulation of synthesis. J. Lipid. Res. 50, 1955-1966.(doi:10.1194/jlr. R900010-JLR200)
67. Lepesheva GI, Waterman MR. 2007 Sterol 14a-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim. Biophys. Acta 1770, 467-477.(doi:10.1016/j. bbagen.2006.07.018)
68. Keber R, Motaln H, Wagner KD, Debeljak N, Rassoulzadegan M, Acimovic J, Rozman D, Horvat S. 2011 Mouse knockout of the cholesterogenic cytochrome P450 lanosterol 14a-demethylase (Cyp51a1) gene resembles Antley-Bixler syndrome. J. Biol. Chem. 286, 29 086-29 097.(doi:10.1074/ jbc.M111.253245)
69. Russell DW. 2003 The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137-174.(doi:10.1146/annurev.biochem.72. 121801.161712)
70. Norlin M, Wikvall K. 2007 Enzymes in the conversion of cholesterol into bile acids. Curr. Mol. Med. 7, 199-218.(doi:10.2174/ 156652407780059168)
71. Norlin M, Andersson U, Bjorkhem I, Wikvall K. 2000 Oxysterol 7a-hydroxylase activity by cholesterol 7a-hydroxylase (CYP7A1). J. Biol. Chem. 275, 34 046-34 053.(doi:10.1074/jbc.M002663200)
72. Ishibashi S, Schwarz M, Frykman PK, Herz J, Russell DW. 1996 Disruption of cholesterol 7a-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acid and vitamin supplementation. J. Biol. Chem. 271, 18 017-18 023.(doi:10.1074/jbc. 271.30.18017)
73. Schwarz M, Lund EG, Setchell KD, Lund EG. 1996 Disruption of cholesterol 7a-hydroxylase gene in mice. II. Bile acid deficiency is overcome by induction of oxysterol 7a-hydroxylase. J. Biol. Chem. 271, 18 024-18 031.(doi:10.1074/jbc. 271.30.18024)
74. Pullinger CR et al. 2002 Human cholesterol 7a-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110, 109-117.
75. Wang J, Freeman DJ, Grundy SM, Levine DM, Guerra R, Cohen JC. 1998 Linkage between cholesterol 7a-hydroxylase and high plasma lowdensity lipoprotein cholesterol concentrations. J. Clin. Invest. 101, 1283-1291.(doi:10.1172/ JCI1343)
76. Couture P, Otvos JD, Cupples LA, Wilson PW, Schaefer EJ, Ordovas JM. 1999 Association of the A-204C polymorphism in the cholesterol 7a-hydroxylase gene with variations in plasma low-density lipoprotein cholesterol levels in the Framingham Offspring Study. J. Lipid. Res. 40, 1883-1889.
77. Srivastava A, Pandey SN, Choudhuri G, Mittal B. 2008 Role of genetic variant A-204C of cholesterol 7a-hydroxylase (CYP7A1 gene) in susceptibility to gallbladder cancer. Mol. Genet. Metab. 94, 83-89.(doi:10.1016/j.ymgme.2007.11.014)
78. Tabata S, Yin G, Ogawa S, Yamaguchi K, Mineshita M, Kono S. 2006 Genetic polymorphism of the cholesterol 7a-hydroxylase gene (CYP7A1) and colorectal adenomas: self defense forces health study. Cancer Sci. 97, 406-410.(doi:10.1111/j. 1349-7006.2006.00182.x)
79. Wu Z, Martin KO, Javitt NB, Chiang JY. 1999 Structure and functions of human oxysterol 7ahydroxylase cDNA and gene CYP7B1. J. Lipid. Res. 40, 2195-2203.
80. Toll A, Shoda J, Axelson M, Sjovall J, Wikvall K. 1992 7a-hydroxylation of 26-hydroxycholesterol, 3b-hydroxy-5-cholestenoic acid, and 3b-hydroxy-5- cholenoic acid by cytochrome P-450 in pig liver microsomes. FEBS. Lett. 296, 73-76. (doi:10.1016/ 0014-5793(92)80406-7)
81. Fex-Svenningsen A, Wicher G, Lundqvist J, Pettersson H, Corell M, Norlin M. 2011 Effects on DHEA levels by estrogen in rat astrocytes and CNS co-cultures via the regulation of CYP7B1-mediated metabolism. Neurochem. Int. 58, 620-624.(doi:10.1016/j.neuint.2011.01.024)
82. Pandak WM, Hylemon PB, Ren S, Marques D, Gil G, Redford K, Mallonee D, Vlahcevic ZR. 2002 Regulation of oxysterol 7a-hydroxylase (CYP7B1) in primary cultures of rat hepatocytes. Hepatology 35, 1400-1408.(doi:10.1053/jhep.2002.33200)
83. Setchell KD et al. 1998 Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7a-hydroxylase gene (CYP1B1) causes severe neonatal liver disease. J. Clin. Invest. 102, 1690-1703.(doi:10.1172/JCI2962)
84. Ueki I, Kimura A, Nishiyori A, Chen H-L, Takei H, Nittono H, Kurosawa T. 2008 Neonatal cholestatic liver disease in an Asian patient with a homozygous mutation in the oxysterol 7a-hydroxylase gene. J. Pediatr. Gastroenterol. Nutr. 46, 465-469.(doi:10.1097/MPG.0b013e31815a9911)
85. Tsaousidou MK et al. 2008 Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration. Am. J. Hum. Genet. 82, 510-515.(doi:10.1016/j. ajhg.2007.10.001)
86. Gåvels M, Olin M, Chowdhary BP, Raudsepp T, Andersson U, Persson B, Jansson M, Bjorkhem I, Eggertsen G. 1999 Structure and chromosomal assignment of the sterol 12a-hydroxylase gene (CYP8B1) in human and mouse: eukaryotic cytochrome P-450 gene devoid of introns. Genomics 56, 184-196.(doi:10.1006/geno.1998.5606)
87. Wikvall K. 1984 Hydroxylations in biosynthesis of bile acids. Isolation of a cytochrome P450 from rabbit liver mitochondria catalyzing 26-hydroxylation of C27-steroids. J. Biol. Chem. 259, 3800-3804.
88. Andersson S, Davis DL, Dahlback H, Jornvall H, Russell DW. 1989 Cloning, structure, and expression of the mitochondrial cytochrome P450 sterol 26- hydroxylase, a bile acid biosynthetic enzyme. J. Biol. Chem. 264, 8222-8229.
89. Cali JJ, Hsieh CL, Francke U, Russell DW. 1991 Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J. Biol. Chem. 266, 7779-7783.
90. Lund EG, Guileyardo JM, Russell DW. 1999 cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl Acad. Sci. USA 96, 7238-7243.(doi:10.1073/pnas. 96.13.7238)
91. Mast N, Reem R, Bederman I, Huang S, DiPatre PL, Bjorkhem I, Pikuleva IA. 2011 Cholestenoic acid is an important elimination product of cholesterol in the retina: comparison of retinal cholesterol metabolism with that in the brain. Invest. Ophthalmol. Vis. Sci. 52, 594-603.(doi:10.1167/ iovs.10-6021)
92. Russell DW. 2000 Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta 1529, 126-135.(doi:10.1016/S1388-1981(00)00142-6)
93. Furster C, Wikvall K. 1999 Identification of CYP3A4 as the major enzyme responsible for 25- hydroxylation of 5b-cholestane-3a,7a,12a-triol in human liver microsomes. Biochim. Biophys. Acta 1437, 46-52.(doi:10.1016/S0005- 2760(98)00175-1)
94. Araya Z, Wikvall K. 1999 6a-Hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes. Biochim. Biophys. Acta 1438, 47-54.(doi:10.1016/S1388- 1981(99)00031-1)
95. Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM. 2001 An essential role for nuclear receptors SXR/PXR in detoxication of cholestatic bile acids. Proc. Natl Acad. Sci. USA 98, 3375-3380.(doi:10.1073/pnas. 051014398)
96. Dussault I, Yoo HD, Lin M, Wang E, Fan M, Batta AK, Salen G, Erickson SK, Forman BM. 2003 Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. Proc. Natl Acad. Sci. USA 100, 833-838.(doi:10.1073/pnas.0336235100)
97. Diczfalusy U et al. 2008 4b-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and gender in Koreans, Swedes and Tanzanians. Pharmacogenet. Genomics 18, 201-208.(doi:10.1097/FPC.0b013e3282f50ee9)
98. Miller WL, Auchus RJ. 2011 The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32, 81-151.(doi:10.1210/er.2010-0013)
99. Miller WL, Bose HS. 2011 Early steps in steroidogenesis: intracellular cholesterol trafficking. J. Lipid. Res. 52, 2111-2135.(doi:10.1194/jlr.R016675)
100. Bose HS, Sugawara T, Strauss III JF, Miller WL. 1996 The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. N. Engl. J. Med. 335, 1870-1878.(doi:10.1056/NEJM199612193352503)
101. Hu MC, Hsu NC, El Hadj NB, Pai CI, Chu HP, Wang CK, Chung BC. 2002 Steroid deficiency syndromes in mice with targeted disruption of Cyp11a1 gene. Mol. Endocrinol. 16, 1943-1950.(doi:10.1210/me. 2002-0055)
102. Tajima T, Fujieda K, Kouda N, Nakae J, Miller WL. 2001 Heterozygous mutation in the cholesterol side chain cleavage enzyme (P450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. J. Clin. Endocrinol. Metab. 86, 3820-3825.(doi:10. 1210/jc.86.8.3820)
103. Katsumata N, Ohtake M, Hojo T, Ogawa E, Hara T, Sato N, Tanaka T. 2002 Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A1) cause congenital adrenal insufficiency in humans. J. Clin. Endocrinol. Metab. 87, 3808-3813.(doi:10.1210/jc.87.8.3808)
104. Hiort O, Holterhus PM, Werner R, Marschke C, Hoppe U, Partsch CJ, Riepe FG, Achermann JC, Struve D. 2005 Homozygous disruption of P450 side-chain cleavage gene (CYP11A1) is associated with prematurity, complete 46,XY sex reversal, and severe adrenal failure. J. Clin. Endocrinol. Metab. 90, 538-541.(doi:10.1210/jc.2004-1059)
105. al Kandari H, Katsumata N, Alexander S, Rasoul MA. 2006 Homozygous mutation of P450 side-chain cleavage enzyme gene (CYP11A1) in 46,XY patient with adrenal insufficiency, complete sex reversal, and agenesis of corpus callosum. J. Clin. Endocrinol. Metab. 91, 2821-2826.(doi:10.1210/jc.2005-2230)
106. Kim CJ, Lin L, Huang N, Quigley CA, AvRuskin TW, Achermann JC, Miller WL. 2008 Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side-chain cleavage enzyme, P450scc. J. Clin. Endocrinol. Metab. 93, 696-702.(doi:10.1210/jc.2007-2330)
107. Rubtsov P, Karmanov M, Sverdlova P, Spirin P, Tiulpakov A. 2009 A novel homozygous mutation in the CYP11A1 gene is associated with late-onset adrenal insufficiency and hypospadias in a 46,XY patient. J. Clin. Endocrinol. Metab. 94, 936-939.(doi:10.1210/jc.2008-1118)
108. Sahakitrungruang T, Tee MK, Blackett PR, Miller WL. 2011 Partial defect in the cholesterol side-chain cleavage enzyme P450scc (CYP11A1) resembling nonclassic congenital lipoid adrenal hyperplasia. J. Clin. Endocrinol. Metab. 96, 792-798.(doi:10. 1210/jc.2010-1828)
109. Parajes S, Kamrath C, Rose IT, Taylor AE, Mooij CF, Dhir V, Grotzinger J, Arlt W, Krone N. 2011 A novel entity of clinically isolated adrenal insufficiency caused by a partially inactivating mutation of the CYP11A1 gene encoding for P450 side-chain cleavage enzyme. J. Clin. Endocrinol. Metab. 96, E1798-E1806.(doi:10.1210/jc.2011-1277)
110. Auchus RJ, Lee TC, Miller WL. 1998 Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J. Biol. Chem. 273, 3158-3165.(doi:10.1074/jbc.273.6.3158)
111. Zhang LH, Rodriguez H, Ohno S, Miller WL. 1995 Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc. Natl Acad. Sci. USA 92, 10 619-10 623.(doi:10.1073/pnas. 92.23.10619)
112. Pandey AV, Miller WL. 2005 Regulation of 17,20- lyase activity by cytochrome b5 and by serine phosphorylation of P450c17. J. Biol. Chem. 280, 13 265-13 271.(doi:10.1074/jbc.M414673200)
113. Auchus RJ. 2001 Genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol. Metab. Clin. North. Am. 30, 101-119.(doi:10.1016/S0889-8529(08)70021-5)
114. Costa-Santos M, Kater CE, Auchus RJ. 2004 Two prevalent CYP17A1 mutations and genotypephenotype correlations in 24 Brazilian patients with 17a-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 89, 49-60.(doi:10.1210/jc.2003-031021)
115. Geller DH, Auchus RJ, Mendonca BB, Miller WL. 1997 The genetic and functional basis of isolated 17,20-lyase deficiency. Nat. Genet. 17, 201-205.(doi:10.1038/ng1097-201)
116. Van Den Akker EL, Koper JW, Boehmer AL, Themmen APN, Verhoef-Post M, Timmerman MA, Otten BJ, Drop SLS, De Jong FH. 2002 Differential inhibition of 17a-hydroxylase and 17,20-lyase activities by three novel missense CYP17A1 mutations identified in patients with P450c17 deficiency. J. Clin. Endocrinol. Metab. 87, 5714-5721.(doi:10.1210/jc.2001-011880)
117. Sherbet DP, Tiosano D, Kwist KM, Hochberg Z, Auchus RJ. 2003 CYP17A1 mutation Glu305Gly causes isolated 17,20-lyase deficiency by selectively altering substrate-binding. J. Biol. Chem. 278, 48 563-48 569.(doi:10.1074/jbc.M307586200)
118. Therrell Jr. BL, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman K, Prentice L, Gonzalez J, Gunn S. 1998 Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 101, 583-590.(doi:10.1542/peds.101.4.583)
119. Speiser PW et al. 2010 Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 95, 4133-4160.(doi:10.1210/jc.2009-2631)
120. Gomes LG, Huang N, Agrawal V, Mendonca BB, Bachega TA, Miller WL. 2009 Extra-adrenal 21- hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 94, 89-95.(doi:10.1210/jc.2008-1174)
121. Bristow J, Tee MK, Gitelman SE, Mellon SH, Miller WL. 1993 Tenascin-X: a novel extracellular matrix protein encoded by the human TNXB gene overlapping CYP21B locus. J. Cell. Biol. 122, 265-278.(doi:10.1083/jcb.122.1.265)
122. Schalkwijk J, Zweers MC, Steijlen PM, Dean WB, Taylor G, van Vlijmen IM, van Haren B, Miller WL, Bristow J. 2001 A recessive form of the Ehlers- Danlos syndrome caused by tenascin-X deficiency. N. Engl. J. Med. 345, 1167-1175.(doi:10.1056/ NEJMoa002939)
123. Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna MT, Lesser M, New MI, White PC. 1992 Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21- hydroxylase deficiency. J. Clin. Invest. 90, 584-595.(doi:10.1172/JCI115897)
124. Tardy V, Menassa R, Sulmont V, Lienhardt-Roussie A, Lecointre C, Brauner R, David M, Morel Y. 2010 Phenotype-genotype correlations of 13 rare CYP21A2 mutations detected in 46 patients affected with 21-hydroxylase deficiency and in one carrier. J. Clin. Endocrinol. Metab. 95, 1288-1300.(doi:10. 1210/jc.2009-1202)
125. White PC, Curnow KM, Pascoe L. 1994 Disorders of steroid 11b-hydroxylase isozymes. Endocr. Rev. 15, 421-438.
126. Mellon SH, Bair SR, Monis H. 1995 P450c11B3 mRNA, transcribed from a third P450c11 gene, is expressed in a tissue-specific, developmentally, and hormonally regulated fashion in the rodent adrenal and encodes a protein with both 11- hydroxylase and 18-hydroxylase activities. J. Biol. Chem. 270, 1643-1649.(doi:10.1074/jbc. 270.4.1643)
127. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel J-M. 1992 A chimaeric 11bhydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355, 262-265.(doi:10.1038/355262a0)
128. Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, White PC. 1992 Glucocorticoidsuppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc. Natl Acad. Sci. USA 89, 8327-8331.(doi:10.1073/pnas.89.17.8327)
129. Mornet E, Dupont J, Vitek A, White PC. 1989 Characterization of two genes encoding human steroid 11b-hydroxylase (P-45011b). J. Biol. Chem. 264, 20 961-20 967.
130. Curnow KM, Mulatero P, Emeric-Blanchouin N, Aupetit-Faisant B, Corvol P, Pascoe L. 1997 The amino-acid substitutions Ser288Gly and Val320Ala convert the cortisol-producing enzyme, CYP11B1, into an aldosterone-producing enzyme. Nat. Struct. Biol. 4, 32-35.(doi:10.1038/nsb0197-32)
131. Bottner B, Denner K, Bernhardt R. 1998 Conferring aldosterone synthesis to human CYP11B1 by replacing key amino-acid residues with CYP11B2- specific ones. Eur. J. Biochem. 252, 458-466.(doi:10.1046/j.1432-1327.1998.2520458.x)
132. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M. 2002 Aromatase: a brief overview. Annu. Rev. Physiol. 64, 93-127.(doi:10.1146/annurev.physiol.64.081601.142703)
133. Grumbach MM, Auchus RJ. 1999 Estrogen, consequences and implications of human mutations in synthesis and action. J. Clin. Endocrinol. Metab. 84, 4677-4694.(doi:10.1210/jc.84.12.4677)
134. Cheshenko K, Pakdel F, Segner H, Kah O, Eggen RI. 2008 Interference of endocrine-disrupting chemicals with aromatase CYP19 expression or activity, and consequences for reproduction of teleost fish. Gen. Comp. Endocrinol. 155, 31-62.(doi:10.1016/j. ygcen.2007.03.005)
135. Clark BJ, Cochrum RK. 2007 The steroidogenic acute regulatory protein as a target of endocrine disruption in male reproduction. Drug. Metab. Rev. 39, 353-370.(doi:10.1080/03602530701519151)
136. Norman AW. 1998 Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am. J. Clin. Nutr. 67, 1108-1110.
137. Cheng JB, Motola DL, Mangelsdorf DJ, Russell DW. 2003 De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxylase. J. Biol. Chem. 278, 38 084-38 093.(doi:10.1074/jbc.M307028200)
138. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. 2004 Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl Acad. Sci. USA 101, 7711-7715.(doi:10. 1073/pnas.0402490101)
139. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 1997 25-Hydroxyvitamin D3 1a-hydroxylase and vitamin D synthesis. Science 277, 1827-1830.(doi:10.1126/science.277.5333.1827)
140. Fu GK, Lin D, Zhang MY, Bikle DD, Shackleton CH, Miller WL, Portale AA. 1997 Cloning of human 25- hydroxyvitamin D 1a-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol. Endocrinol. 11, 1961-1970.(doi:10.1210/me. 11.13.1961)
141. Fu GK, Portale AA, Miller WL. 1997 Complete structure of the human gene for the vitamin D 1a-hydroxylase, P450c1a. DNA Cell. Biol. 16, 1499-1507.(doi:10.1089/dna.1997.16.1499)
142. Shinki T, Shimada H, Wakino S, Anazawa H, Hayashi M, Saruta T, DeLuca HF, Suda T. 1997 Cloning and expression of rat 25-hydroxyvitamin D3 1ahydroxylase cDNA. Proc. Natl Acad. Sci. USA 94, 12 920-12 925.(doi:10.1073/pnas.94.24.12920)
143. St-Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH. 1997 The 25-hydroxyvitamin D 1a-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J. Bone Miner. Res. 12, 1552-1559.(doi:10.1359/jbmr. 1997.12.10.1552)
144. Wang JT, Lin CJ, Burridge SM, Fu GK, Labuda M, Portale AA, Miller WL. 1998 Genetics of vitamin D 1a-hydroxylase deficiency in 17 families. Am. J. Hum. Genet. 63, 1694-1702.(doi:10. 1086/302156)
145. Kitanaka S et al. 1998 Inactivating mutations in the 25-hydroxyvitamin D3 1a-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N. Engl. J. Med. 338, 653-661.(doi:10.1056/ NEJM199803053381004)
146. Kim CJ, Kaplan LE, Perwad F, Huang N, Sharma A, Choi Y, Miller WL, Portale AA. 2007 Vitamin D 1a-hydroxylase gene mutations in patients with 1a-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 92, 3177-3182.(doi:10.1210/jc.2006-2664)
147. Edouard T, Alos N, Chabot G, Roughley P, Glorieux FH, Rauch F. 2011 Short- and long-term outcome of patients with pseudo-vitamin D deficiency rickets treated with calcitriol. J. Clin. Endocrinol. Metab. 96, 82-89.(doi:10.1210/jc.2010-1340)
148. Ramagopalan SV et al. 2011 Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann. Neurol. 70, 881-886.(doi:10.1002/ana.22678)
149. Schlingmann KP et al. 2011 Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N. Engl. J. Med. 365, 410-421.(doi:10.1056/ NEJMoa1103864)
150. Dauber A, Nguyen TT, Sochett E, Cole DEC, Horst R, Abrams SA, Carpenter TO, Hirschhorn JN. 2012 Genetic defect in CYP24A1, the vitamin D 24- hydroxylase gene, in a patient with severe infantile hypercalcemia. J. Clin. Endocrinol. Metab. 97, E268-E274.(doi:10.1210/jc.2011-1972)
151. Stoilov I, Jansson I, Sarfarazi M, Schenkman JB. 2001 Roles of cytochrome P450 in development. Drug Metabol. Drug Interact. 18, 33-55.(doi:10. 1515/DMDI.2001.18.1.33)
152. McNeilly AD, Woods JA, Ibbotson SH, Wolf CR, Smith G. 2012 Characterization of a human keratinocyte HaCaT cell line model to study the regulation of CYP2S1. Drug Metab. Dispos. 40, 283-289.(doi:10.1124/dmd.111.042085)
153. Duester G. 2007 Retinoic acid regulation of the somitogenesis clock. Birth Defects. Res. C Embryo. Today 81, 84-92.(doi:10.1002/bdrc.20092)
154. Marshall H, Morrison A, Studer M, Popperl H, Krumlauf R. 1996 Retinoids and Hox genes. FASEB J. 10, 969-978.
155. Sakai Y, Meno C, Fujii H, Nishino J, Shiratori H, Saijoh Y, Rossant J, Hamada H. 2001 The retinoic acid-inactivating enzyme CYP26A1 is essential for establishing an uneven distribution of retinoic acid along the anterio-posterior axis within the mouse embryo. Genes Dev. 15, 213-225.(doi:10.1101/ gad.851501)
156. Roberts C, Ivins S, Cook AC, Baldini A, Scambler PJ. 2006 Cyp26a1, Cyp26b1 and Cyp26c1 genes are down-regulated in Tbx1 null mice and inhibition of CYP26 enzyme function produces a phenocopy of DiGeorge Syndrome in the chick. Hum. Mol. Genet. 15, 3394-3410.(doi:10.1093/ hmg/ddl416)
157. Ribes V et al. 2007 Rescue of P450 oxidoreductase (Por)-null mouse reveals functions in vasculogenesis, brain and limb patterning linked to retinoic acid homeostasis. Dev. Biol. 303, 66-81.(doi:10.1016/j.ydbio.2006.10.032)
158. MacLean G, Li H, Metzger D, Chambon P, Petkovich M. 2007 Apoptotic extinction of germ cells in testes of Cyp26b1 knockout mice. Endocrinology 148, 4560-4567.(doi:10.1210/en.2007-0492)
159. Laue K et al. 2011 Craniosynostosis and multiple skeletal anomalies in humans and zebrafish result from a defect in the localized degradation of retinoic acid. Am. J. Hum. Genet. 89, 595-606.(doi:10.1016/j.ajhg.2011.09.015)
160. Pennimpede T, Cameron DA, MacLean GA, Li H, Abu-Abed S, Petkovich M. 2010 The role of CYP26 enzymes in defining appropriate retinoic acid exposure during embryogenesis. Birth Defects. Res. A Clin. Mol. Teratol. 88, 883-894.(doi:10.1002/bdra.20709)
161. Uehara M, Yashiro K, Takaoka K, Yamamoto M, Hamada H. 2009 Removal of maternal retinoic acid by embryonic CYP26A1, 26B1 and 26C1 activity is required for correct Nodal expression during early embryonic patterning. Genes Dev. 23, 1689-1698.(doi:10.1101/gad.1776209)
162. Stoilov I, Akarsu AN, Sarfarazi M. 1997 Identification of three different truncating mutations in cytochrome P450 1B1 (CYP1B1) as the principal cause of primary congenital glaucoma (buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. 6, 641-647.(doi:10.1093/hmg/6.4.641)
163. Libby RT, Smith RS, Savinova OV, Zabaleta A, Martin JE, Gonzalez FJ, John SWM. 2003 Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science 299, 1578-1581.(doi:10.1126/science.1080095)
164. Stark K, Dostalek M, Guengerich FP. 2008 Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide. FEBS J. 275, 3706-3717.(doi:10.1111/j.1742-4658. 2008.06518.x)
165. Nelson DR, Goldstone JV, Stegeman JJ. 2013 The cytochrome P450 genesis locus: the origin and evolution of animal cytochrome P450s. Phil. Trans. R. Soc. B 368, 20120474.(doi:10.1098/rstb. 2012.0474)
166. Jiang JH, Jia WH, Qin HD, Liang H, Pan ZG, Zeng YX. 2004 Expression of cytochrome P450 enzymes in human nasopharyngeal carcinoma and non-cancerous nasopharynx tissue. Ai Zheng 23, 672-677.
167. Stark K, Wu ZL, Bartleson CJ, Guengerich FP. 2008 mRNA distribution and heterologous expression of 'orphan' cytochrome P450 20A1. Drug Metab. Dispos. 36, 1930-1937.(doi:10.1124/dmd. 108.022020)
168. Hwang JT, Baik SH, Choi JS, Lee KH, Rhee SK. 2011 Genetic traits of avascular necrosis of the femoral head analyzed by array comparative genomic hybridization and real-time polymerase chain reaction. Orthopedics 34, 14.
169. Guengerich FP, Cheng Q. 2011 Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology. Pharmacol. Rev. 63, 684-699.(doi:10.1124/pr.110.003525)